Skip to main content
. 2016 Sep 16;31(1):113–118. doi: 10.1038/eye.2016.199

Table 2. Clinical Fefatures of Ophthalmic Giant Cell Arteritis.

  African-Americana (n=32) Caucasianb Odds Ratio (95% CI) P-valuec
Systemic Symptomsd n=85
 Fever 2/19 (11%) 12 (14%) 0.72 (0.15, 3.50) 1.00
 Weight loss 10/25 (40%) 29 (34%) 1.29 (0.51, 3.22) 0.59
 Malaise 5/19 (26%) 27 (32%) 0.77 (0.25, 2.35) 0.79
 Anorexia 4/18 (22%) 25 (29%) 0.69 (0.21, 2.29) 0.77
 Headache 21/28 (75%) 38 (45%) 3.71 (1.43, 9.66) <0.01
 Jaw claudication 9/29 (31%) 46 (54%) 0.38 (0.16, 0.93) 0.03
 Neck pain 9/16 (56%) 11 (13%) 8.65 (2.68, 28.0) <0.001
 Scalp tenderness 7/29 (24%) 15 (18%) 1.48 (0.54, 4.11) 0.44
 Myalgia 3/18 (17%) 12 (14%) 1.22 (0.31, 4.84) 0.72
 Anemia (Hgb<11 g/dl) 10/29 (34%) 12 (14%) 3.20 (1.20, 8.53) 0.02
         
Ophthalmic Symptoms n=84
 Amaurosis fugax 5 (16%) 26 (31%) 0.42 (0.15, 1.21) 0.16
 Acute vision loss 25 (78%) 82 (98%) 0.09 (0.02, 0.45) <0.001
 Diplopia (transient or permanent) 4 (13%) 5 (6%) 2.29 (0.57, 9.12) 0.25
 Eye pain 9 (28%) 7 (8%) 4.36 (1.46, 13.0) <0.01
         
Ophthalmic Signs n=84
 Anterior ischemic optic neuropathy 20 (63%) 68 (81%) 0.39 (0.16, 0.96) 0.04
 Central retinal artery occlusion 4 (13%) 12 (14%) 0.87 (0.26, 2.92) 1.00
 Posterior ischemic optic neuropathy 2 (6%) 6 (7%) 0.88 (0.17, 4.59) 1.00
a

Not all systemic symptom data was collected for all African-American patients.

b

Published cohort18 Individual headings indicate the number of patients.

c

Fisher's exact test when there are five or fewer patients with any race/characteristic combination, χ2-test otherwise.

d

Systemic symptoms data was not available for the single African-American patient, thus the Caucasian group includes the single African-American patient (n=85) for these comparisons.